

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

005453

OFFICE OF PESTICIOES AND TOXIC SUBSTANCES

.20%

	!
Date:	May 27, 1983
Subject:	EPA Registration Number: 10445-31 TK-100 Liquid Concentrate
Prom:	Deloris F. Graham A44 - 6/17/83 PHB/TSS とらいれる
To:	Henry Jacoby Product Manager (21)
	Applicant: Calgon Corporation. P.O. Box 1346 Pittsburgh, PA 15230
	Active Ingredients: 2-(4-thiazolyl)benzimidazole, as the hypophosphite salt
	Inert Ingredient

Background: Submitted Acute Oral, Acute Dermal, Acute Inhalation, Eye Irritation and Primary Skin Irritation studies. Data under Accession Number 249806. Cite-All Method of Support.

Recommendation:

- (1) PHB/TSS finds these data unacceptable to support conditional registration of this product.
 - a. In the Acute Oral, Acute Dermal and Acute Inhalation and Primary Skin Studies, method of procedure, dosage, individual symptomatology and necropsy reports, LC50 and 95% confidence limits must be submitted.
 - b. In the Eye Irritation Study, nine animals (six with treated unwashed eyes and three with treated washed eyes) must be used. Method of procedure must be submitted.

Label:

(1) Labeling comments reserved until acceptable data are submitted.

120

Review:

(1) Acute Oral Toxicity Study: Wells Laboratories, Inc.; Lab. # D-4293; September 10, 1970.

Procedure must be submitted. Exact doses used could not be determined. However, it was stated that the LD₅₀ was 5300 mg/kg, with 19/20 confidence limits between 5100 and 5510 mg/kg.

Study Classification: Core Supplementary Data. Procedure methods must be submitted. Doses must be given. Individual symptomatology and necropsy report for each animal must be submitted also.

(2) Acute Dermal Toxicity Study: Wells Laboratories, Inc.; Lab # D-4296; September 10, 1970.

<u>Procedure:</u> Four young adult rabbits weighing between 2.5 kilograms per each of three groups received one of the following doses: 5000; 10,000; or 20,000 mg/kg. Test material was applied to abraded skin under occlusive wrap for 24-hour exposure. Observations were made for two weeks after treatment.

Results: No mortalities. Mild to moderate hyperemia and slight edema and moderate sloughing. Hair regrewth showed no aberrations.

Study Classification: Core Supplementary Data. Five male and five temales per dose must be used. Individual symptomatology and necropsy reports for each animal must be submitted. LD50 and 95% confidence limits for males and females individually must be submitted.

(3) Primary Skin Irritation Study: Wells Laboratories; Lab. # F-369; October 15, 1983.

Procedure: See U.S. Department of Agriculture, Federal Insecticide, Fungicide and Rodenticide Act, Section 362.3 of the regulations (7 CFR Part 363), paragraph (c).

Results: No irritation. Primary Skin Irritation Index = 0.3.

Study Classification: Core Supplementary Data. Method of procedure including dosage used must be given.

(4) Eye Irritation Study: Wells Laboratories; Lab. # F-370; October 19, 1973.

Procedure: See U.S. Department of Agriculture, Federal Insecticide, Fungicide and Rodenticide Act, Section of 363.116 regulations (7 CFR part 363) paragraph (d). Dose: 0.1 ml in one eye of each of six rabbits.

Results: No irritation.

Study Classification: Core Supplementary Data. Method of procedure must be submitted along with results. Nine animals (six with treated unwashed eyes and three with treated washed eyes) must be used.

(5) Acute Inhalation Toxicity Study: Wells Laboratories; Lab. # P-371; October 26, 1973.

Procedure: See U.S.D.A. Regulation 362.8, Title 7, Chapter III, part 362, Code of Federal Regulations. Ten rats inhaled 2 mg/liter for one hour.

Results: All animals (5M and 5F per dose) survived at the following doses: 2 4 and 6 ml/liter. No sign of toxicity observed and no gross findings at necropsy.

Study Classification: Core Supplementary Data. Actual concentrations in mg/l must be used. LC50 and 95% confidence limits for males and females must be submitted.

THIABENDAZOLE	 060101
THIABENDAZOLE	
Page 4 is not included in this copy.	
Pages through are not include	ed.
The material not included contains information:	the following t
Identity of product inert ingredient	ts.
Identity of product impurities.	
Description of the product manufactu	uring process.
Description of quality control proce	edures.
Identity of the source of product in	ngredients.
Sales or other commercial/financial	information.
A draft product label.	
The product confidential statement of	of formula.
Information about a pending registra	ation action.
FIFRA registration data.	,
The document is a duplicate of page	(s)
The document is not responsive to the	he request.